Molecular Templates, Inc.

Informe acción NasdaqCM:MTEM

Capitalización de mercado: US$7.8m

Molecular Templates Dirección

Dirección controles de criterios 3/4

El CEO de Molecular Templates' es Eric Poma , nombrado en Jan 2009, tiene una permanencia de 15.25 años. compensación anual total es $1.55M, compuesta por 38.8% salario y 61.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.34% de las acciones de la empresa, por valor de $28.69K. La antigüedad media del equipo directivo y de la junta directiva es de 0.7 años y 6.7 años, respectivamente.

Información clave

Eric Poma

Chief Executive Officer (CEO)

US$857.8k

Compensación total

Porcentaje del salario del CEO72.4%
Permanencia del CEO15.4yrs
Participación del CEO0.3%
Permanencia media de la direcciónless than a year
Promedio de permanencia en la Junta Directiva6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Apr 03
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Dec 20
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Apr 17
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Aug 14
Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Aug 11

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Apr 29
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Dec 30
Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Nov 25
Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Sep 22
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Aug 15
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Mar 21
Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Feb 21
Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Jan 26
Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Dec 22

Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay

Dec 04
Here's What We Think About Molecular Templates' (NASDAQ:MTEM) CEO Pay

Molecular Templates: Progress Stalled As Partial Hold Placed On Pivotal ETB Trial

Nov 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Poma en comparación con los beneficios de Molecular Templates?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$858kUS$621k

-US$8m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$600k

-US$93m

Sep 30 2022n/an/a

-US$81m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$577k

-US$83m

Sep 30 2021n/an/a

-US$101m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$5mUS$560k

-US$105m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$107m

Mar 31 2020n/an/a

-US$85m

Dec 31 2019US$2mUS$515k

-US$69m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$4mUS$500k

-US$30m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$448k

-US$24m

Compensación vs. Mercado: La compensación total ($USD857.77K) de Eric está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD661.15K).

Compensación vs. Ingresos: La compensación de Eric ha sido consistente con los resultados de la empresa en el último año.


CEO

Eric Poma (52 yo)

15.4yrs

Permanencia

US$857,769

Compensación

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Eric Poma
CEO, Chief Scientific Officer & Director15.4yrsUS$857.77k0.28%
$ 21.8k
Jason Kim
President1.4yrsUS$579.24k0.097%
$ 7.5k
Kristen Quigley
Chief Operating Officerless than a yearsin datossin datos
Grace Kim
Chief Strategy Officer & Head of IRless than a yearsin datossin datos
Michelle Iwamoto-Fan
Senior Vice President & General Counselless than a yearsin datossin datos
Joseph Phillips
Senior VP & Head of CMC Developmentno datasin datossin datos
Chris Moore
Senior VP and Head of Preclinical Development & Translational Medicineless than a yearsin datossin datos

0.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MTEM no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Eric Poma
CEO, Chief Scientific Officer & Director6.8yrsUS$857.77k0.28%
$ 21.8k
Michel Klein
Member of Scientific Advisory Boardno datasin datossin datos
David Hoffmann
Independent Director6.8yrsUS$59.29k0%
$ 0
Harold Selick
Independent Chairman6.8yrsUS$87.29k0.041%
$ 3.2k
Kevin Lalande
Independent Director6.8yrsUS$54.29k0%
$ 0
Corazon Sanders
Independent Director4.5yrsUS$49.29k0%
$ 0
Burkhard Jansen
Member of Scientific Advisory Boardno datasin datossin datos
Neil Berinstein
Member of Scientific Advisory Boardno datasin datossin datos
Gabriela Gruia
Director2.3yrsUS$561.35k0%
$ 0

6.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de MTEM se considera experimentada (6.7 años de antigüedad promedio).